Reperfusion Injury vs. ST Elevation at 1 Week Post-PCI

What is reperfusion injury?

• No-reflow phenomenon (microvascular obstruction)
• Arrhythmias (particularly accelerated idioventricular rhythm and VF) occurring within the first minutes to hours of reperfusion
• Microvascular damage and cardiomyocyte death

So what causes ST elevation at ~1 week post-PCI?

1. Early post-MI pericarditis (Epistenocardiac pericarditis)

• Occurs 1–3 days after a large, transmural MI
• Caused by pericardial inflammation overlying the necrotic zone
• Rare in the primary PCI era (early reperfusion limits infarct size)
• Presents with diffuse ST elevation (saddle-shaped), pleuritic chest pain, pericardial rub
• Braunwald's Heart Disease: "It is rare in the primary PCI era and is now seen after large, transmural MIs due to absent or late/failed reperfusion."

2. Dressler syndrome (Late post-MI pericarditis)

• Occurs 1 week to a few months after MI — this is the timeframe in your question
• Immune-mediated (autoantibodies against cardiac antigens released by necrotic myocardium)
• Presents with: fever, pleuritic chest pain, pericardial rub, pericardial/pleural effusion, elevated CRP
• Can produce diffuse ST elevation on ECG (pericarditic pattern)
• Incidence has dropped dramatically in the reperfusion era (<1% of MIs)
• More common after large MIs — i.e., patients where PCI was late or failed
• Goldman-Cecil Medicine: "Pericarditis developing later (2 to 10 weeks) after acute MI could represent Dressler syndrome, which is believed to be immune mediated."

3. Stent thrombosis / re-occlusion

• Can cause recurrent ST elevation at any time post-PCI
• Acute/subacute stent thrombosis (within hours–days) or late stent thrombosis (>30 days)
• Associated with re-elevation of cardiac biomarkers and acute ischemic symptoms
• Requires emergency angiography

4. Left ventricular aneurysm

• Persistent ST elevation (weeks to months after large anterior MI) is a classic sign of LV aneurysm formation from infarct expansion
• Unlike ischemic ST elevation, this is persistent/fixed and not associated with ongoing symptoms or biomarker rise
• Confirmed with echocardiography

Summary Table

• Cover the most recent ACS guidelines and evidence available in the medical textbooks in this library (which include up-to-date sources like Harrison's 2025, Braunwald's Heart Disease, and Goldman-Cecil Medicine)
• Help you look up specific ACS topics — management, antithrombotic therapy, risk stratification, NSTEMI vs STEMI protocols, etc.

• 2021 — ACC/AHA Guideline for Coronary Artery Revascularization (replaced the 2011 CABG + 2011 PCI guidelines)
• 2022 — AHA/ACC/HFSA Guideline for Heart Failure (separate topic)
• 2023 — ACC/AHA Guideline for the Diagnosis and Management of NSTEMI/UA (Non-ST-Elevation Acute Coronary Syndromes) — this was a significant focused update
• 2023 — AHA/ACC updates on antithrombotic therapy in ACS

• ACC.org
• AHA Professional Heart Daily
• Circulation journal

Latest Updates in Acute Coronary Syndrome (ACS)

1. DIAGNOSIS & RISK STRATIFICATION

High-Sensitivity Troponin (hs-cTn) — 0/1h and 0/2h Protocols

• ESC 2020/2023 recommends the 0h/1h algorithm (hs-cTnI or hs-cTnT) as the preferred rule-out/rule-in strategy
• A 0h result below the limit of detection + low clinical probability = rule-out at 0h (no 1h sample needed)
• 0h/2h algorithm is the recommended alternative
• The older 0h/3h and 0h/6h protocols are now reserved for standard-sensitivity assays
• Key trials: APACE, HiSTORIC, RAPID-TnT

Validated Risk Scores

• GRACE 2.0 remains the gold standard for mortality risk in NSTEMI — 6-month and 1-year mortality prediction
• HEART score widely adopted in emergency settings for rapid disposition
• TIMI score is simpler but less discriminatory; still used
• ESC 2023 NSTEMI guideline emphasizes GRACE ≥140 = high risk → early invasive strategy within 24h

Type 2 MI Recognition

• Increased emphasis on distinguishing Type 1 MI (plaque rupture) from Type 2 MI (supply-demand mismatch — e.g., sepsis, tachyarrhythmia, severe anemia)
• Type 2 MI does not benefit from antiplatelet intensification or PCI in most cases
• Troponin elevation alone is not sufficient — clinical context is mandatory

2. ANTITHROMBOTIC & ANTIPLATELET THERAPY

P2Y12 Inhibitor Selection

DAPT Duration — Evolving Evidence

• Standard: 12 months DAPT post-ACS
• De-escalation strategy (ESC 2023): switching from ticagrelor/prasugrel → clopidogrel at 1–3 months is reasonable in high bleeding risk patients (HOST-REDUCE-POLYTECH-ACS, TROPICAL-ACS trials)
• Abbreviated DAPT (1–3 months) followed by P2Y12 monotherapy acceptable in very high bleeding risk (STOPDAPT-2 ACS, TWILIGHT-ACS)
• Aspirin-free strategies: Growing evidence for dropping aspirin and continuing P2Y12 monotherapy after short DAPT (GLOBAL LEADERS, TWILIGHT)

Anticoagulation

• Unfractionated heparin (UFH) or bivalirudin during PCI — both acceptable
• Fondaparinux preferred for initial medical management of NSTEMI (OASIS-5) — lower bleeding risk vs. enoxaparin
• Enoxaparin acceptable alternative
• Routine use of GP IIb/IIIa inhibitors (tirofiban, eptifibatide) no longer recommended upfront — reserved for bail-out during PCI (thrombotic complications)

3. REPERFUSION STRATEGY

STEMI

• Primary PCI remains the gold standard — target door-to-balloon ≤90 min (≤120 min if transferred)
• Pharmacoinvasive strategy (thrombolysis + PCI within 3–24h) when primary PCI not available within 120 min
• Complete revascularization of non-culprit lesions is now recommended (Class I, ESC 2023):
  • COMPLETE trial (2019): staged complete revascularization reduced CV death/MI vs. culprit-only
  • Timing: can be done at index procedure or staged during same hospitalization

NSTEMI — Timing of Invasive Strategy (ESC 2023 Update)

• Key change: The previous "urgent" 2h strategy is now reserved for truly very high-risk patients
• VERDICT trial and TIMACS: no benefit of ultra-early (<12h) vs. early (12–72h) in non-very-high-risk patients

Radial vs. Femoral Access

• Transradial access is the default recommended approach (Class I) — lower major bleeding, lower mortality in STEMI (MATRIX, RIFLE-STEACS trials)

4. SPECIAL POPULATIONS

Cardiogenic Shock

• IABP-SHOCK II: Intra-aortic balloon pump (IABP) does NOT improve mortality in cardiogenic shock — no longer routinely recommended (Class III)
• ECMO/Impella: No clear mortality benefit in RCTs (ECMO-CS, IMPRESS, EURO SHOCK) — individualized use
• Early revascularization of culprit only in shock (CULPRIT-SHOCK trial): culprit-only PCI preferred over immediate multivessel PCI in cardiogenic shock

Elderly Patients (>75 years)

• Benefit of invasive strategy preserved even in very elderly (MOSCA, SENIOR trials)
• Lower doses of prasugrel (5mg) if used; prefer ticagrelor or clopidogrel
• Bleeding risk tools (ARC-HBR criteria) should guide DAPT decisions

Diabetes

• No significant change in revascularization strategy
• SGLT2 inhibitors and GLP-1 agonists now integral to post-ACS care in diabetics (cardiovascular outcome benefit independent of glycemic control)

5. POST-ACS SECONDARY PREVENTION

Lipid Lowering

• LDL target: <55 mg/dL (1.4 mmol/L) AND >50% reduction from baseline — ESC 2019/2021
• High-intensity statin (atorvastatin 40–80mg, rosuvastatin 20–40mg) initiated immediately
• If LDL not at goal: add ezetimibe (IMPROVE-IT trial)
• If still not at goal: add PCSK9 inhibitor (evolocumab/alirocumab) — ODYSSEY OUTCOMES, FOURIER trials show significant MACE reduction

Anti-inflammatory Therapy — Emerging Area

• Colchicine 0.5mg daily post-MI: LoDoCo2 and COLCOT trials demonstrate ~25% reduction in recurrent MACE
• ESC 2021 gives colchicine a Class IIa recommendation for secondary prevention post-MI
• Icosapentaenoic acid (IPE / Vascepa): REDUCE-IT trial — 4g/day reduces MACE in high-risk patients with elevated triglycerides

Beta-Blockers — Reassessment

• Long-standing Class I recommendation now being reconsidered:
• REDUCE-AMI trial (2024): Beta-blockers did NOT reduce death or MI in patients with preserved EF post-STEMI — a major finding challenging decades of practice
• Current position: Still reasonable in reduced EF (HFrEF) post-MI; may not be necessary in preserved EF patients without arrhythmia or other indication

ACE Inhibitors / ARBs

• Recommended in all ACS patients with EF <40%, hypertension, diabetes, or CKD
• Not routinely required if EF preserved and no comorbidities

Cardiac Rehabilitation

• Class I recommendation — significantly reduces mortality, improves exercise capacity and quality of life
• Underutilized globally

6. NEWER/EMERGING AREAS

Key Guideline Documents to Reference

Important caveat: My training extends to early 2024. For any guideline published after that — particularly any 2024 ACC/AHA ACS-specific update — verify at ACC.org or ESC.org.The most impactful paradigm-shifting updates to highlight from recent years:

1. REDUCE-AMI (2024): Beta-blockers may not be needed post-STEMI with preserved EF — challenges 30+ years of standard practice
2. Complete revascularization in STEMI (COMPLETE trial) — now Class I
3. Colchicine post-MI (COLCOT, LoDoCo2) — now Class IIa for secondary prevention
4. DAPT de-escalation/abbreviation — shorter courses with P2Y12 monotherapy increasingly supported
5. PCSK9 inhibitors in all very-high-risk ACS patients not at LDL goal
6. Culprit-only PCI in cardiogenic shock (CULPRIT-SHOCK) — not multivessel at index procedure

Why UFH is Preferred Over Enoxaparin During PCI

1. Real-Time Monitoring with ACT (Activated Clotting Time)

• UFH anticoagulant effect can be monitored at the bedside in the cath lab using ACT
• Target ACT during PCI: 250–350 seconds (or 200–250s if GP IIb/IIIa inhibitor used)
• Enoxaparin has no reliable point-of-care monitoring tool — anti-Xa levels require a lab and take time; not practical during an active procedure
• This real-time titratability is critical during a procedure where over- or under-anticoagulation can have immediate consequences

2. Rapid, Complete Reversibility with Protamine

• UFH is fully reversible with protamine sulfate within minutes — essential if:
  • Arterial access site bleeding occurs
  • Emergency CABG is needed
  • Tamponade or perforation develops during the procedure
• Protamine only partially reverses enoxaparin (~60% of anti-IIa activity, poor reversal of anti-Xa activity) — making it unreliable in urgent bleeding situations

3. Dose Titration During the Procedure

• UFH can be redosed in real time based on ACT measurements
• Enoxaparin has a fixed subcutaneous or weight-based IV dosing with a prolonged half-life (~4–6 hours) — difficult to adjust during a procedure

4. Predictable Pharmacokinetics in the Cath Lab Context

• If the patient received enoxaparin pre-procedure (e.g., in NSTEMI management), the residual anti-Xa level is unknown at the time of PCI
• Guidelines (ESC, ACC/AHA) recommend:
  • If last enoxaparin dose <8h ago → no additional anticoagulant needed
  • If last dose 8–12h ago → additional 0.3 mg/kg IV enoxaparin
  • If last dose >12h ago → treat as if no anticoagulation
• This complexity contrasts with UFH, where you simply dose by weight and check ACT

5. Short Half-Life

• UFH IV half-life: ~1 hour (dose-dependent)
• Enoxaparin half-life: ~4–6 hours
• Shorter half-life means anticoagulation wears off quickly after sheath removal → lower risk of access site hematoma and major bleeding post-procedure

Summary Table

Is Enoxaparin Ever Used in PCI?

• It was already started pre-procedure for ACS management
• Operator preference / institutional protocol
• ATOLL trial showed non-inferior outcomes with IV enoxaparin vs. UFH in STEMI-PCI